Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer

Area of Science:

• Oncology
• Immunology
• Cancer Genetics

Background:

• Immunotherapy, including immune checkpoint inhibition and vaccines, is under investigation for prostate cancer.
• Current clinical trials indicate limited responsiveness of prostate cancers to immunotherapy.
• Prostate cancer's significant pathological and genetic heterogeneity is a potential cause of this resistance.

Purpose of the Study:

• To investigate the hypothesis that driver oncogenic signaling pathways influence prostate cancer progression, immunity, and resistance to immunotherapy.
• To explore strategies for overcoming tumor immunity and expanding patient eligibility for immunotherapy.

Main Methods:

• Analysis of the role of driver oncogenic signaling pathways in prostate cancer.
• Evaluation of the relationship between tumor genetics, pathology, and immune response.
• Proposed combination therapy of immunotherapy with targeted pathway inhibitors.

Main Results:

• Prostate cancer's heterogeneity contributes to poor immunotherapy response.
• Specific tumor types may respond differently to immune-based strategies based on clinical stage, grade, and genetics.
• Oncogenic pathways are implicated in regulating tumor immunity and therapeutic resistance.

Conclusions:

• Targeting oncogenic driver pathways in combination with immunotherapy offers a promising strategy to enhance clinical responses in prostate cancer.
• Identifying responsive tumors based on pathological and genetic criteria is crucial for effective immune-based therapies.
• Combined modality treatments hold potential for overcoming immunotherapy resistance in prostate cancer.